A5060172013- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease and Transplantation
- Liver Disease Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Organ Transplantation Techniques and Outcomes
- Gallbladder and Bile Duct Disorders
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Central Venous Catheters and Hemodialysis
- Venous Thromboembolism Diagnosis and Management
- Pancreatic and Hepatic Oncology Research
- MRI in cancer diagnosis
- Vascular Procedures and Complications
- Radiopharmaceutical Chemistry and Applications
- Radiation Dose and Imaging
- Pediatric Hepatobiliary Diseases and Treatments
- Renal cell carcinoma treatment
- Renal Transplantation Outcomes and Treatments
- Transplantation: Methods and Outcomes
- Medical Imaging and Pathology Studies
- Colorectal Cancer Treatments and Studies
- Esophageal and GI Pathology
- Lung Cancer Treatments and Mutations
- Vascular anomalies and interventions
University of California, San Francisco
2015-2024
University of California System
2011-2024
Stanford University
2023
University of California, San Diego
2023
UCSF Helen Diller Family Comprehensive Cancer Center
2019
University of California San Francisco Medical Center
2016
University of San Francisco
2016
Society of Interventional Radiology
2013
Bayer (United States)
2013
American Association of Neurological Surgeons
2013
We report on the long-term intention-to-treat (ITT) outcome of 118 patients with hepatocellular carcinoma (HCC) undergoing downstaging to within Milan/United Network for Organ Sharing T2 criteria before liver transplantation (LT) since 2002 and compare results 488 listed LT HCC meeting at listing in same period. The subgroups include 1 lesion >5 ≤8 cm (n = 43), 2 or 3 lesions least one >3 ≤5 total tumor diameter 61), 4-5 each ≤3 14). In group, 64 (54.2%) had received 5 (7.5%) developed...
Four patients with inoperable hepatocellular carcinoma were treated a magnetic targeted carrier bound to doxorubicin (MTC-DOX) by using joint resonance (MR) imaging/conventional angiography system consisting of 1.5-T short-bore magnet connected C-arm unit sliding tabletop. Selective transcatheter delivery the MTC-DOX hepatic artery was monitored intraprocedural MR imaging, and interim catheter manipulation performed fluoroscopic guidance optimize agent tumor minimize normal tissue. The final...
Mixed hepatocellular cholangiocarcinoma (HCC-CC) and intrahepatic (I-CC) are increasingly being reported in patients with cirrhosis. The aims of this study were (1) to evaluate the incidence, imaging features, posttransplant outcomes for who underwent transplantation carcinoma (HCC) found have HCC-CC or I-CC explant (2) compare these those controls HCC matched (1:3) by tumor size number nodules explant. In specimens 10 302 (3.3%) liver (LT) HCC, mixed was identified. There 4 additional...
Transarterial chemoembolization (TACE) is one of the standard therapies for bridging patients with hepatocellular carcinoma (HCC) to transplantation. This study was designed determine which features on pre- and post-TACE imaging are associated tumor necrosis in pathological specimens. Records 105 132 HCC lesions who underwent liver transplantation after TACE were retrospectively reviewed. In 70% nodules, >90% achieved. The development lesion upon analysis avid enhancement (P = 0.03) presence...
With the growing use of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT), there are many unanswered questions regarding patient selection. In this document, we review literature on in neuroendocrine tumors (NETs) different primary origin, discuss issues
Radiosurgery requires precise lesion localization. Fiducial markers enable tracking, but complications from insertion may occur. The purpose of this study was to describe fiducial marker into pulmonary lesions.Clinical and imaging records 28 consecutive patients with 32 lung nodules or masses who underwent a total 59 before radiosurgery were retrospectively reviewed.Eighteen (67%) developed pneumothorax, six (22%) required chest tube. rates pneumothorax 82% 40%, respectively, when 18-gauge...
The purpose of this study was to determine the rate and risk factors for development irreversible hepatotoxicity after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) synthetic hepatic dysfunction. Two hundred fifty-one consecutive HCC dysfunction who underwent 443 TACE procedures from 2005 2010 were retrospectively reviewed. included met one following criteria: a pre-TACE bilirubin level ≥ 2 mg/dL, an international normalized ratio (INR) > 1.5,...
Patients with T1 hepatocellular carcinoma (HCC; 1 lesion < 2 cm) are currently not eligible for priority listing liver transplantation (LT). A common practice is to wait without locoregional therapy (LRT) until tumor growth occurs from T2 (1 2‐5 cm or 2‐3 lesions ≤ 3 be Model End‐Stage Liver Disease exception. We aimed evaluate the intention treat outcome of “wait and ablate” approach nonresection candidates HCC T2. The study included 114 patients 1.0‐1.9 followed by serial imaging every...
Transarterial radioembolization (TARE) with yttrium-90 (90Y) microspheres has been widely adopted for the treatment of HCC. Recent advances in dosimetry have led to durable local responses. Radiation segmentectomy become a viable alternative thermal ablation early-stage HCC (Barcelona Clinic Liver Cancer 0 and A) commonly used as bridge transplant. TARE is also downstaging transplant using traditional lobar radiation techniques. lobectomy dual role tumor control induction contralateral liver...
To retrospectively determine if patients with a history of intraoperative bile duct injury or liver transplantation have an increased risk for arterial (AI) during percutaneous transhepatic cholangiography (PTC) and biliary drainage (PTBD) compared the AI established in 1970s 1980s.This study was approved by committee on human research deemed compliant Health Insurance Portability Accountability Act. The informed consent requirement waived. Records 1394 procedures (307 PTCs, 1087 PTBDs)...